CN1323344A - 治疗再狭窄的DNAzyme和方法 - Google Patents

治疗再狭窄的DNAzyme和方法 Download PDF

Info

Publication number
CN1323344A
CN1323344A CN99811966A CN99811966A CN1323344A CN 1323344 A CN1323344 A CN 1323344A CN 99811966 A CN99811966 A CN 99811966A CN 99811966 A CN99811966 A CN 99811966A CN 1323344 A CN1323344 A CN 1323344A
Authority
CN
China
Prior art keywords
dnazyme
restenosis
angioplasty
onset
myc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99811966A
Other languages
English (en)
Chinese (zh)
Inventor
L·-Q·孙
M·J·凯恩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Research Pty Ltd
Original Assignee
Johnson and Johnson Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Research Pty Ltd filed Critical Johnson and Johnson Research Pty Ltd
Publication of CN1323344A publication Critical patent/CN1323344A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
CN99811966A 1998-08-13 1999-08-12 治疗再狭窄的DNAzyme和方法 Pending CN1323344A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9637498P 1998-08-13 1998-08-13
US60/096374 1998-08-13

Publications (1)

Publication Number Publication Date
CN1323344A true CN1323344A (zh) 2001-11-21

Family

ID=22257071

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99811966A Pending CN1323344A (zh) 1998-08-13 1999-08-12 治疗再狭窄的DNAzyme和方法

Country Status (8)

Country Link
EP (1) EP1117768A4 (fr)
JP (1) JP2002525037A (fr)
KR (1) KR20010072475A (fr)
CN (1) CN1323344A (fr)
AU (1) AU5298499A (fr)
CA (1) CA2340322A1 (fr)
WO (1) WO2000009672A1 (fr)
ZA (1) ZA200101188B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ201499A0 (en) * 1999-08-04 1999-08-26 Unisearch Limited Treatment of inflammatory and malignant diseases
JP2002348235A (ja) * 2001-03-23 2002-12-04 Clinical Supply:Kk 再狭窄予防剤
DE10346487A1 (de) * 2003-10-02 2005-05-12 Transmit Technologietransfer Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
WO2007000676A2 (fr) * 2005-06-28 2007-01-04 Johnson & Johnson Research Pty. Ltd. Oligonucléotides riches en guanosine en tant qu'agents pour l'induction de mort cellulaire dans des cellules eucaryotes
DK3093022T3 (da) 2015-05-15 2019-11-04 Sterna Biologicals Gmbh & Co Kg Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma
EP4271393A4 (fr) * 2020-12-30 2025-01-22 The Regents of the University of California Axnzyme biologiquement stable atténuant efficacement l'expression génique dans des cellules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
DE69429087T2 (de) * 1993-01-07 2002-07-11 Thomas Jefferson University, Philadelphia Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
WO1998049346A1 (fr) * 1997-04-29 1998-11-05 The Scripps Research Institute Molecules d'adn enzymatiques
DE69940903D1 (de) * 1998-03-27 2009-07-02 Johnson & Johnson Res Pty Ltd Diagnostische methoden basierend auf katalytischen nukleinsäuren

Also Published As

Publication number Publication date
WO2000009672A9 (fr) 2000-05-18
WO2000009672A1 (fr) 2000-02-24
EP1117768A4 (fr) 2003-09-03
JP2002525037A (ja) 2002-08-13
AU5298499A (en) 2000-03-06
KR20010072475A (ko) 2001-07-31
ZA200101188B (en) 2002-05-13
CA2340322A1 (fr) 2000-02-24
EP1117768A1 (fr) 2001-07-25

Similar Documents

Publication Publication Date Title
US20220267765A1 (en) Treatment of genetic disorders associated with dna repeat instability
US7662948B2 (en) Antisense oligonucleotides against VR1
CN101448945A (zh) 用于诱导外显子跳跃的手段和方法
US20090197336A1 (en) Suppression of polymorphic alleles
US6103890A (en) Enzymatic nucleic acids that cleave C-fos
US6087484A (en) Enhancement of ribozyme catalytic activity by A 2'-O-substituted facilitator oligonucleotide
WO1998032846A9 (fr) Traitement par acides nucleiques enzymatiques des maladies ou des etats lies aux niveaux de c-fos
CN1323344A (zh) 治疗再狭窄的DNAzyme和方法
WO1994011494A1 (fr) Oligonucleotides antisens utilises pour inhiber l'expression de genes de collagene ayant subis une mutation et de type sauvage
US7138378B1 (en) Genetic suppression and replacement
US6770753B2 (en) Phosphorothioate antisense heparanase oligonucleotides
US5861502A (en) Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
AU661124B2 (en) Enhancement of ribozyme catalytic activity by a neighboring facilitator oligonucleotide
US20040072783A1 (en) Nucleozymes with endonuclease activity
US6238917B1 (en) Asymmetric hammerhead ribozymes
JP2005510204A (ja) ヘアレス蛋白質発現を阻害するための核酸及びその使用方法
AU721758B2 (en) Asymmetric hammerhead ribozymes
JPH1059996A (ja) 白血病性芽細胞のアポトーシスをもたらす分化誘導物質と結合した、人のｃ−ｆｅｓ プロト癌遺伝子の一次転写に相補的なアンチセンスオリゴヌクレオチド及びその用法
WO1999027087A1 (fr) Oligonucleotides anti-sens specifiques de la cdk4
WO1998049287A2 (fr) Oligonucleotides antisens specifiques d'une thymidylate synthase
CA3004710C (fr) Compositions et methodes permettant de traiter le syndrome de l'x fragile et des syndromes associes
WO2001079441A9 (fr) Inactivation de genes par methylation d'adn ciblee
Usman et al. Nucleozymes
WO2001034793A1 (fr) Methode de realisation d'epissage d'adn
HK1131186A (en) Means and method for inducing exon-skipping

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication